We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

688385:SSEShanghai Fudan Microelectronics Group Co., Ltd. Class A Analysis

Data as of 2026-03-16 - not real-time

CN¥70.15

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

The stock is trading at ¥70.15, well below its 20‑day (¥80.17) and 50‑day (¥81.09) simple moving averages, indicating short‑term weakness, while still sitting above the 200‑day average (¥61.58) which keeps the longer‑term bias neutral. RSI at 33.6 suggests the shares are approaching oversold territory, but the bearish MACD histogram and decreasing volume signal lingering downside pressure. Volatility is elevated at nearly 50% over the past 30 days, yet the beta of 0.05 reflects minimal correlation with broader market moves, making price swings more company‑specific.
Fundamentally, the company appears heavily overvalued with a trailing PE of 135 versus an industry average of 34, and a price‑to‑book of 9.3. Operating margins are deep in the red (‑34%), cash flow is flat, and debt‑to‑equity is high at 23, raising concerns about financial resilience. The dividend yield is a modest 0.11% with a low payout ratio, but given the cash‑heavy balance sheet and weak earnings, dividend sustainability is doubtful. Forward earnings are expected to improve, yet the combination of high valuation, weak profitability, and sector‑specific regulatory headwinds suggests caution.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • price below short‑term moving averages
  • bearish MACD and decreasing volume
  • extremely high PE relative to peers

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • modest revenue growth and forward EPS upside
  • persistent operating losses and high leverage
  • elevated volatility but low market beta

Long Term

> 3 years
Neutral
Model confidence: 4/10

Key Factors

  • strategic importance of semiconductor capabilities in China
  • potential policy support offset by valuation premium
  • uncertain path to profitability and cash‑flow generation

Key Metrics & Analysis

Financial Health

Revenue Growth5.70%
Profit Margin5.83%
P/E Ratio134.9
ROE3.48%
Debt/Equity22.97
P/B Ratio9.3
Industry P/E34.2

Technical Analysis

TrendNeutral
RSI33.6
SupportCN¥68.02
ResistanceCN¥88.88
MA 20CN¥80.17
MA 50CN¥81.09
MA 200CN¥61.58
MACDBearish
VolumeDecreasing
Fear & Greed Index78.57

Valuation

GradeOvervalued
TypeBlend
Dividend Yield0.11%

Risk Assessment

Beta0.05
Volatility49.64%
Sector RiskHigh
Reg. RiskHigh
Geo RiskHigh
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.